Dateline City:
VIENNA
C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Nave and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1
VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the first presentation of data from C-SURFER, the
companys Phase 2/3 clinical trial evaluating the investigational
once-daily treatment regimen of grazoprevir (100mg) and elbasvir (50mg)
in patients with advanced chronic kidney disease (CKD) infected with
chronic hepatitis C virus (HCV) genotype 1 (GT1).1
Treatment-nave patients and patients who failed prior pegylated
interferon HCV therapy, with or without cirrhosis, all of whom had
Language:
English
Contact:
Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more